Skip to main content
Midas Edge

Enliven Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

ELVN$49.43+10.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

Incorporated by Reference
ExhibitNumberExhibit DescriptionFormFile No.ExhibitFiling Date
4.1Form of Pre-Funded Warrant8-K001-392474.1March 19, 2024
10.1+*Sam Kintz Confirmatory Employment Letter, as amended and restated February 29, 202410-K001-3924710.6March 14, 2024
10.2+*Helen Collins Confirmatory Employment Letter, as amended and restated February 29, 202410-K001-3924710.7March 14, 2024
10.3+*Benjamin Hohl Confirmatory Employment Letter, as amended and restated February 29, 202410-K001-3924710.8March 14, 2024
10.4+*Joseph Lyssikatos Confirmatory Employment Letter, as amended and restated February 29, 202410-K001-3924710.9March 14, 2024
10.5+*Anish Patel Confirmatory Employment Letter, as amended and restated February 29, 202410-K001-3924710.10March 14, 2024
10.6+Sam Kintz Change in Control and Severance Agreement, as amended and restated February 29, 202410-K001-3924710.11March 14, 2024
10.7+Helen Collins Change in Control and Severance Agreement, as amended and restated February 29, 202410-K001-3924710.12March 14, 2024
10.8+Benjamin Hohl Change in Control and Severance Agreement, as amended and restated February 29, 202410-K001-3924710.13March 14, 2024
10.9+Joseph Lyssikatos Change in Control and Severance Agreement, as amended and restated February 29, 202410-K001-3924710.14March 14, 2024
10.10+Anish Patel Change in Control and Severance Agreement, as amended and restated February 29, 202410-K001-3924710.15March 14, 2024
10.11+Outside Director Compensation Policy, as amended February 13, 202410-K001-3924710.16March 14, 2024
10.12*Securities Purchase Agreement, dated March 19, 2024, by and among the Company and the Purchasers named therein8-K001-3924710.1March 19, 2024
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith
32.1**Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith
32.2**Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith
101.INSINLINE XBRL Instance DocumentFurnished herewith
101.SCHINLINE XBRL Taxonomy Extension Schema with Embedded Linkbase DocumentsFurnished herewith
104Cover Page Interactive Data File (embedded within the Inline XBRL document)Furnished herewith
+Management contract or compensatory plan.
*Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6).
**The certifications attached as Exhibits 32.1 and 32.2 that accompany this quarterly report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Enliven Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.